CVS Health ($CVS)'s Caremark pharmacy benefit manager reached a settlement with the Federal Trade Commission requiring changes to its rebate practices and future integration with the TrumpRx program. Under the agreement, Caremark will offer clients the option to opt out of rebate-based payment models and, once regulations are implemented, count eligible TrumpRx purchases toward health plan deductibles. Lobbying disclosures show CVS continued engaging policymakers in early 2026 on pharmacy benefit managers, prescription drug pricing, Medicare, and broader healthcare policy.
- Caremark agreed to provide clients an option to opt out of rebate-based payment models.
- Eligible TrumpRx purchases will count toward deductibles once supporting regulations are finalized.
- FTC Chairman Andrew Ferguson said the settlement is expected to generate billions of dollars in drug cost savings.
- TrumpRx.gov launched in February to provide discounted branded and generic prescription drugs.
- The settlement follows a similar FTC agreement reached earlier this year with Cigna.
Relevant Companies
- CVS Health ($CVS) - Caremark must modify its rebate practices and integrate eligible TrumpRx purchases into deductibles.
- Cigna ($CI) - Its Evernorth PBM reached a similar FTC settlement earlier this year.
- Eli Lilly ($LLY) - Its weight-loss drugs are among the medications promoted through TrumpRx.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
